WAVEMAN · COMPANY

ALMS · Alumis Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

ALMS

Name: ALUMIS INC. (ALMS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

ALUMIS INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001847367

ACTIVIST 13DFORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$534.3K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

106

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

-1011.7%

CONVERSIONS · 180D

codes C/M, not in net · $203.9K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$534.3K over 180 days

-$534.3K over 90 days

below 57% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

106 funds added or opened last quarter

more than 68% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

-1011.7% net margin

below 89% of Pharma & Biotech

BUYBACKS

$17.0K repurchased, FY to 2025-12-31

below 99% of Pharma & Biotech

SHORT

6.1 days to cover · settled 2026-07-31

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$534.3K across 6 people in 180 days.

106 funds added or opened positions in the latest 13F quarter, of 199 holders.

Foresite Capital Fund VI LP disclosed a 5%+ stake (3.5%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +136.2%

+136.2%12M

INSIDER BUYINSIDER SELL13D/G STAKEFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows a net $534.3K sold by insiders over 180 days, 106 funds added last quarter, $140.0K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ALUMIS INC. insiders sold a net $534.3K of stock across 62 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Bradley Mark Christopher

Chief Development Officer

SELL

2026-08-03

2,572.0

$67.8K

Drappa Jorn

Chief Medical Officer

SELL

2026-08-03

2,447.0

$64.5K

Goldstein David M

Chief Scientific Officer

SELL

2026-08-03

2,596.0

$68.5K

Hardiman Roy C.

Chief Business & Strategy Ofcr

SELL

2026-08-03

2,692.0

$71.0K

Pangali Sanam

Chief Legal Officer

SELL

2026-08-03

1,364.0

$36.0K

62 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 57 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

AyurMaya Capital Management Company, LP

15,139,707.0 sh

$426.0M

BlackRock, Inc.

8,218,151.0 sh

$231.3M

FMR LLC

6,769,170.0 sh

$190.5M

Deep Track Capital, LP

6,348,558.0 sh

$178.6M

SAMSARA BIOCAPITAL, LLC

6,345,219.0 sh

$178.6M

5%+ owners

13D = intent to influence · 13G = passive

Foresite Capital Fund VI LP

ACTIVIST 13D · 2026-08-17

3.5%

Foresite Capital Management VI, LLC

ACTIVIST 13D · 2026-08-17

3.5%

Foresite Capital Fund V, L.P.

ACTIVIST 13D · 2026-08-17

5.6%

Foresite Capital Management V, LLC

ACTIVIST 13D · 2026-08-17

5.6%

Foresite Capital Opportunity Fund V, L.P.

ACTIVIST 13D · 2026-08-17

5.4%

Planned sales · Form 144

Filed before the sale — intent, not a trade

SANAMPREET PANGALI

FILED 2026-07-06

$140.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Dorsey Wright Healthcare Momentum ETF

$2.6M POSITION · AS OF 2026-04-30

2.1%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$4.9M POSITION · AS OF 2026-03-31

1.6%

Virtus Biotech Clinical Trials Etf

$593.1K POSITION · AS OF 2026-04-30

1.6%

PROFUND VP PHARMACEUTICALS

$156.6K POSITION · AS OF 2026-03-31

1.5%

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

$161.7K POSITION · AS OF 2026-04-30

1.3%

Invesco Dorsey Wright SmallCap Momentum ETF

$3.8M POSITION · AS OF 2026-02-28

1.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 13 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

2 ACTIVE

Phase 3

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12
REVENUE	$24.1M	—	—
OPERATING INCOME	$-453.8M	$-300.8M	$-158.2M
NET INCOME	$-243.3M	$-294.2M	$-155.0M
EPS (DILUTED)	-2.86	-10.38	-72.08
OPERATING CASH FLOW	$-369.5M	$-255.1M	$-130.0M
CASH	$89.7M	$169.5M	$46.0M
BUYBACKS	$17.0K	$6.0K	$64.0K

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE